Sri Lanka has proposed reviving its Preferential Trade Agreement (PTA) with Bangladesh to boost trade between the two countries.
Foreign Affairs, Foreign Employment and Tourism Minister Vijitha Herath made the proposal at talks with Bangladesh’s State Minister for Foreign Affairs, Humaiun Kobir, at the Foreign Ministry in Colombo on 18 November, according to the Ministry.
Herath also asked Bangladesh to support wider cooperation in trade, commerce, education and tourism. He invited Bangladesh to send a business delegation to Expo 2027, and Kobir agreed to support that, the Ministry said.
Kobir, for his part, proposed that Sri Lanka consider a government-to-government agreement to buy medicines directly from Bangladeshi pharmaceutical manufacturers.
He noted that both countries have faced economic challenges and stressed the importance of closer collaboration. He also welcomed the Sri Lankan government’s Clean Sri Lanka and Prajashakthi programmes and said poverty alleviation is a priority both countries share.
After the talks, the two sides signed a Memorandum of Understanding (MoU) to set up the Bangladesh-Sri Lanka Joint Consultative Commission for Comprehensive Cooperation. Both sides reaffirmed their commitment to closer ties, recalling that diplomatic relations were established in 1972.
Background
A preferential trade agreement is a deal under which two or more countries cut or remove tariffs on selected goods traded between them. It is narrower than a full free trade agreement, which usually covers most goods and often services and investment as well.
The reports of the meeting do not give the terms of the earlier agreement or say why it needs reviving, and the Ministry did not say when any talks on the proposal would begin. Sri Lanka and Bangladesh are both members of regional groupings in South Asia, and both are among the countries in the region that have had to manage economic pressures in recent years.
Bangladesh is one of the larger economies in South Asia, and its pharmaceutical industry is among its established export sectors. The medicines proposal made by Kobir would be a separate arrangement from any tariff agreement, because it concerns government purchasing rather than trade rules.
What it means
At this stage the discussions are proposals and a signed framework for consultation, not new trade rules. Nothing in the Ministry’s account suggests that tariffs or import conditions have changed for traders or consumers.
If a revived agreement is eventually concluded, it would be expected to affect the cost and range of goods traded between the two countries, which could matter to importers, exporters and shoppers. The offer on medicines, if taken up, would concern how the state buys pharmaceuticals, a matter that bears on public hospital supplies. For now, readers should treat both ideas as under discussion, and the new Joint Consultative Commission is the body set up to take forward cooperation between the two governments.